The keys to successful CDMO collaboration during development
When drug development companies prepare to enter the clinical phase, they must produce both the Drug Substance (API) and the Drug Product (IMP). Since many organizations lack the in-house capabilities for this, they often turn to Contract Development and Manufacturing Organizations (CDMOs) to handle the production.
How can you successfully source these services and select the CDMO best suited to your needs? Join us to hear from speakers with experience in contracting and working with CDMOs and gain valuable insights into best practices and strategies.
Program
Program to be announced.
Time & Place
Date: 17 March 2026
Time: 9:00-17:00
Venue: Medicon Village, Lund
Registration fee
Early fee: 3500 SEK excl VAT for registration latest on February 3, 2026 then 4500 SEK excl VAT.
Program Committee
Jessica Elversson, BioInvent
Nelly Fransén, Arex Advisor
Agneta Larhed, Regsmart Life Science
Tuulikki Lindmark, TuuLifeScience
Maria Lundin-Johnson, Meribel Pharma Solutions
Swedish Pharmaceutical Society – The Section Drug Formulation
In cooperation with
